Selected Open Clinical Trials

To learn more about Fox Chase’s clinical trial program, including a complete list of open trials, visit

Breast Cancer

REP0210: A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery
Lori J. Goldstein, MD

Gastrointestinal Cancer (Colorectal)

GI-063: A Phase I Study Evaluating the Maximal Tolerated Dose of Intra-hepatic Drug Eluting Irinotecan Beads (DEBIRI) for the Treatment of Colorectal Liver Metastases in Patients with Metastatic Colon Cancer with Liver Only or Liver Predominant Disease
Efrat Dotan, MD

Gastrointestinal Cancer (Pancreas)

RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer (NCT01739439)
Joshua E. Meyer, MD

Genitourinary Cancer (Bladder)

A Phase II Trial of Dovitinib in BCG Refractory Urothelial Carcinoma Patients with Tumor FGFR3 Mutations or Over-Expression: Hoosier Oncology Group GU12-157
Richard E. Greenberg, MD

Genitourinary Cancer (Prostate)

BNIT-PRV-301: A Randomized, Double-Blind, Phase III Efficacy Trial of PROSTVAC-V/F+GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
Marijo Bilusic, MD, PhD

(CIRB) CALGB 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Rosalia Viterbo, MD 

Genitourinary Cancer (Renal)

AGS-003-007: An International Phase III Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
David Y.T. Chen, MD

Gynecologic Cancer (Ovarian)

GYN-064: A Phase I/II Trial of Weekly Paclitaxel in Combination with Ganetespib in Patients with Recurrent or Persistent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 120407)(NCT01962948)
Lainie P. Martin, MD

Head and Neck Cancer

10311: A Phase I Study of MLN8237 in Combination with Cetuximab and Definitive Radiation in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Igor Astsaturov, MD

A Prospective Longitudinal Study of Swallowing Function in Head and Neck Cancer Patients
Miriam N. Lango, MD

FER-HN-027: Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, with Correlative Studies in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01316757)
Ranee Mehra, MD

Hematologic Cancer (Leukemia)

A Phase I/II, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI 110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Patricia L. Kropf, MD

Leukemia SPORE Phase I/II Randomized Study of Decitabine versus Decitabine and Carboplatin versus Decitabine and Arsenic, for Relapsed, Refractory and Elderly AML and MDS
Patricia L. Kropf, MD


AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma
Margaret von Mehren, MD

Thoracic Cancer (Non-Small Cell Lung)

FER-TH-036: A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, in Combination with Erlotinib in Patients with Recurrent or Metastatic Non-Small Cell Lung Cancer (IND 111879) (NCT01471964)
Hossein Borghaei, DO

MK-3475-010: A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
Hossein Borghaei, DO

NP28761: A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK Rearranged Non-Small Cell Lung Cancer Previously Treated with Crizotinib
Hossein Borghaei, DO

GO28754: A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, DO

CLDK378X2102: A Phase Ib, Open-Label, Dose Escalation Study of LDK378 and AUY922 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
Ranee Mehra, MD